INmune Bio upgraded to Buy from Neutral at Lucid Capital
Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune’s pipeline for the upgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on INMB:
- Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
- INmune Bio Highlights CORDStrom RDEB Program and IP Strength
- INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
- INmune Bio to Present New CORDStrom Phase III Data
- INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic Adds 2 Sentences to Claude Code to Stop AI Video Game Clones

Ripple Partner Reaches One Million People With Safe Water

NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:58 AM

VIPCross-Asset Positioning Amid AI Earnings Scrutiny and the US Election
1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.

